---

SWOT Analysis: India's National Immunisation Programme (UIP)

---

STRENGTHS

• The UIP is the world's largest immunisation programme, vaccinating approximately 26.5 million infants and 29 million pregnant women annually across all states and union territories.
• A vast network of public health centres, sub-centres, Anganwadi centres, and outreach sessions ensures delivery at the last mile.

• Full immunisation coverage rose from 62% in 2015 to 98.4% as of January 2026 (PIB, Government of India), one of the steepest climbs globally.
• Zero-dose children as a proportion of the total population fell from 0.11% (2023) to 0.06% (2024).

• Backed by the Ministry of Health & Family Welfare (MoHFW) with dedicated funding under the National Health Mission (NHM).
• The National Technical Advisory Group on Immunisation (NTAGI) provides evidence-based vaccine introduction decisions.
• Vaccines are provided free of cost to all beneficiaries.

• The UIP covers 12 vaccine-preventable diseases including BCG, OPV, Pentavalent (DPT-HepB-Hib), IPV, Rotavirus, PCV, Measles-Rubella, JE, and Td vaccines.
• Recent additions: HPV vaccine (for cervical cancer prevention) and an indigenously manufactured Td vaccine.

• eVIN (Electronic Vaccine Intelligence Network): AI-powered real-time tracking of vaccine stocks and cold-chain temperatures; has reduced vaccine stockouts by ~80%.
• U-WIN Portal: Digital health ID for tracking individual immunisation status, modelled on CoWIN.
• HMIS integration for monitoring and evaluation.

• Launched in 2014 to reach the under-immunised; has vaccinated over 5.46 crore (54.6 million) children and 1.32 crore (13.2 million) pregnant women through intensified rounds.

• Polio-free status certified in 2014 (no case since 2011).
• Maternal and Neonatal Tetanus Eliminated (2015).
• Yaws-free declaration in 2016 (first country globally).
• Measles-Rubella Champion Award received in 2024 from the global M&R Partnership.

• India is a major global vaccine producer (Serum Institute, Bharat Biotech, etc.), reducing import dependency and supporting affordability.

---

WEAKNESSES

• Coverage remains uneven across states; high-burden states like Bihar, UP, Rajasthan, MP, and Jharkhand persistently lag behind national averages.
• Urban slum populations, migrant workers, nomadic and homeless communities remain hard to reach despite NUHM efforts.

• Last-mile cold-chain infrastructure in remote, tribal, and hilly areas is still inadequate.
• Power supply interruptions affect refrigeration reliability at peripheral health facilities.

• Overburdened ANMs (Auxiliary Nurse Midwives) handle immunisation alongside multiple other duties.
• Limited supervisory visits by Medical Officers to Primary/Urban Health Centres, reducing quality oversight.
• Skill gaps in administering newer vaccines (e.g., injectable IPV, PCV).

• Discrepancies between HMIS and survey-based estimates; beneficiary data especially scarce in urban settings.
• OTP-related issues and late data entry into U-WIN affect real-time tracking.
• Lack of a dedicated M&E person for urban immunisation in many states (e.g., Rajasthan, per the CUIP 2024 review).

• Dropout between first and final vaccine doses remains a challenge, particularly for multi-dose schedules (e.g., Pentavalent, OPV).

• Religious/cultural beliefs and misinformation drive vaccine hesitancy in isolated communities.
• Rumour management and AEFI (Adverse Events Following Immunisation) communication remain reactive rather than proactive.

---

OPPORTUNITIES

• Nationwide HPV vaccination rollout offers a major opportunity to reduce cervical cancer burden.
• mRNA technology and next-generation vaccine platforms (e.g., mucosal vaccines) can be integrated for future VPDs.
• Introduction of Varicella, Hepatitis A, Typhoid Conjugate Vaccine (TCV), and pneumococcal boosters are under consideration.

• Expansion of U-WIN to all districts enables lifelong digital immunisation records.
• AI-powered microplanning (using geospatial and household survey data) can identify zero-dose pockets with precision.
• Integration with Ayushman Bharat Digital Mission (ABDM) creates a unified health ID.

• India's Zero-Immunisation Programme (ZIP) directly targets unreached populations; already showing results with a 3 percentage-point increase in DPT1 coverage.
• International support from GAVI and WHO for reaching zero-dose children.

• The massive CoWIN infrastructure and public trust built during COVID-19 vaccination can be leveraged for routine immunisation outreach.
• Lessons in demand generation, beneficiary tracking, and adverse event communication are directly applicable.

• Opportunity to integrate climate-resilient cold-chain infrastructure (solar-powered ILRs) into immunisation systems.
• Early warning systems for outbreak response can be embedded into eVIN/U-WIN platforms.

• India can export its immunisation model (Mission Indradhanush, eVIN) to other LMICs and strengthen South-South cooperation.
• India's vaccine manufacturing capacity positions it as the "pharmacy of the world" for routine and pandemic vaccines.

---

THREATS

• Social media-driven misinformation and AEFI rumours can quickly erode trust, as seen in localized refusals during MR campaigns.
• Rising anti-vaccine sentiment, especially in urban educated populations influenced by global anti-vax narratives.

• COVID-19 caused a significant disruption to routine immunisation in 2020-21, with missed cohorts requiring catch-up campaigns.
• Future pandemic threats could once again strain routine immunisation infrastructure.

• Budget pressures within NHM can affect procurement, cold-chain maintenance, and frontline worker incentives.
• Competing priorities (NCDs, COVID, TB elimination) may divert attention from routine immunisation.

• Dependence on complex multi-tier cold-chain for temperature-sensitive vaccines (particularly rotavirus, PCV) creates vulnerability.
• Natural disasters (floods, cyclones) in endemic states can disrupt supply chains.

• Nomadic communities, migrant construction/brick kiln workers, and urban homeless remain structurally excluded from routine outreach.
• Conflict-affected or flood-prone areas present persistent access barriers.

• Measles outbreaks reported in several states (2023-25) highlight that even high national coverage can mask sub-national pockets of susceptibility.
• Importation risk from neighbouring countries with ongoing poliovirus circulation (Pakistan, Afghanistan) threatens polio-free status.

• Sociocultural resistance to HPV vaccination in conservative communities due to its association with sexual activity.
• Operational challenges in targeting adolescent girls through school-based programmes (school dropout, private school inclusion).

---

Summary Table

---

• PIB, Government of India - Jan 2026 press release: Full immunisation coverage at 98.4%
• Jacob John T & Kompithra RZ (2025). India's universal immunization program: A review of successes, challenges, and future directions. Indian J Med Microbiol. PMID: 40252840
• Tawde PP et al. (2024). Developments and Trends of Immunization in India. Cureus. PMID: 39252742
• CUIP Review Report 2024 (ITSU/MoHFW): Urban immunisation gaps and M&E challenges